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Accessed November 1, 2014.A Mechanistic Explanation
for the Minimal Impact of
Renal Denervation on 24-h
Ambulatory Blood Pressure
in SIMPLICITY HTN-3Explanations for the lack of signiﬁcant lowering of
24-h ambulatory blood pressure following renal
denervation in SYMPLICITY HTN-3 (Renal Denerva-
tion in Patients With Uncontrolled Hypertension)
have been offered, including the unanticipated fall
in ambulatory BP in the sham operated group,
perhaps as a result of a Hawthorne effect or placebo
effect (1). Alternatively, the recognized individual
variation in renal nerve anatomy may have led to
inadequate renal denervation in a large proportion of
patients, because it is not yet practical or routine to
conﬁrm successful renal denervation following the
clinical procedure (1,2). I would like to offer an
alternative explanation, with clinical implications.
The majority of patients enrolled in SYMPLICITY
HTN-3 were obese, deﬁned as body mass index (BMI)
>30 kg/m2. The mean BMI in the renal denervation
group was 34.2  6.5 kg/m2. Although sympathetic
nerve activity, including renal sympathetic nerve
activity, is known to be elevated in human obesity
(3,4), sympathetic activity is not greater in obese
patients with hypertension compared with those
without hypertension. That is, renal sympathetic
activation may not play a mechanistic role in the
development of hypertension associated with com-
mon human obesity. This contrasts markedly with
the situation in lean humans. In lean patients with
hypertension, renal sympathetic nerve activity is
markedly increased compared with lean normoten-
sive humans, in whom renal sympathetic nerve
activity is not elevated (5). Renal sympathetic nerve
activation may play a central role in the develop-
ment of hypertension in lean, but not obese, pa-
tients. I wonder if a post-hoc analysis (with all the
pitfalls of such an analysis) of SYMPLICITY HTN-3
might be illuminating. When stratiﬁed by BMI, isthere a lean cohort that particularly beneﬁts from
renal denervation?*Holly R. Middlekauff, MD
*David Geffen School of Medicine at UCLA
UCLA School of Medicine
Medicine (Cardiology)
A2-237 CHS
10833 Le Conte Avenue
Los Angeles, California 90095-3075
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tension 2007;50:862–8.REPLY: A Mechanistic Explanation forthe Minimal Impact of Renal Denervation
on 24-h Ambulatory Blood Pressure in
SIMPLICITY HTN-3
We appreciate Dr. Middlekauff’s interest in the re-
sults of SYMPLICITY HTN-3 (Renal Denervation in
Patients With Uncontrolled Hypertension) and her
thoughtful letter suggesting an alternative explana-
tion for the failure to demonstrate a beneﬁt of renal
denervation based on ambulatory blood pressure
monitoring. The research cited by Esler et al. (1)
and Lambert et al. (2) provides interesting evi-
dence that the role of sympathetic nervous system
hyperactivity in the etiology of essential hyperten-
sion is different between obese and lean patients with
hypertension. However, the clinical implications of
the difference in sympathetic nerve ﬁring between
obese and lean hypertensive patients are unknown.
We undertook a post-hoc analysis of the blood
pressure–lowering effect of renal denervation com-
pared with sham control according tertiles of body
mass index (BMI). No differences between renal de-
nervation and sham were found. Further exploration
of results in patients with a normal BMI (#27 kg/m2)
also revealed no difference between denervation and
TABLE 1 Comparison of Outcomes at 6 Months Based on BMI
Ambulatory Blood
Pressure, mm Hg Denervation Sham p Value
BMI >38 kg/m2 n ¼ 87 n ¼ 30
SBP 8.20  15.93 9.79  15.91 0.64
DBP 5.13  9.50 6.05  9.92 0.65
BMI $30 to #38 kg/m2 n ¼ 151 n ¼ 86
SBP 6.56  15.41 3.28  18.91 0.17
DBP 3.94  9.73 2.58  10.77 0.32
BMI <30 kg/m2 n ¼ 87 n ¼ 42
SBP 5.64  13.73 4.50  14.20 0.66
DBP 3.34  7.95 2.06  8.67 0.41
BMI >27 to <30 kg/m2 n ¼ 42 n ¼ 23
SBP 2.13  14.63 3.22  14.79 0.78
DBP 2.42  8.58 1.24  8.97 0.60
Values are mean  SD.
BMI ¼ body mass index; DBP ¼ diastolic blood pressure; SBP ¼ systolic blood
pressure.
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960sham groups (Table 1). We did observe a smaller,
albeit nonsigniﬁcant, fall in ambulatory blood pres-
sure among lean compared with obese subjects in
both treatment groups.
The adipocyte produces aldosterone, so we inves-
tigated the effect of spironolactone according to BMI
(3). Spironolactone use produced no signiﬁcant dif-
ferences in ambulatory blood pressure endpoints be-
tween obese and normal weight patients. Moreover,
among the denervation subgroup receiving spi-
ronolactone at baseline, there was no difference in
blood pressure change between the obese (n ¼ 26;
BMI >38 kg/m2) and the lean (n ¼ 21; BMI <30 kg/m2)
patients (8.3  12.5 mm Hg vs. 10.4  13.7 mm Hg;
p ¼ 0.59). Additionally, spironolactone in obese sham
subjects (n ¼ 14) failed to provide a signiﬁcant drop in
blood pressure compared with lean sham subjects
receiving spironolactone (n ¼ 8; 9.4  15.7 mm Hg
vs. 0.3  19.5 mm Hg; p ¼ 0.22).
Given the overall neutral results of SYMPLICITY
HTN-3 (4,5), it is difﬁcult to draw any meaningful
conclusions from these data. Additional post-hoc
analysis of SYMPLICITY HTN-3 data by our group
have proposed several potential factors, including
those involving procedural factors, medication
adherence, and patient subgroups. These analyses
further highlight the importance of well-designed,
randomized, sham-controlled clinical trials to clarify
our understanding of the potential role for renal
denervation in the management of uncontrolled hy-
pertension in obese and lean patients.*George L. Bakris, MD
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Timing Should Be ConsideredWe read the recent report by Thiele et al. (1) with
great interest. The investigators performed a multi-
center, randomized trial to compare the adjunctive
aspiration thrombectomy (AT) with conventional
percutaneous coronary intervention (PCI) in patients
with non–ST-segment elevation myocardial in-
farction (NSTEMI). Patients presented within 72 h
after symptom onset and with thrombus over culprit
lesion demonstrated by angiography were enrolled.
